Active Filter(s):
Details:
Amathus will be responsible for identifying and progressing novel chaperone activators through preclinical discovery. Merck has the option to acquire Amathus Therapeutics and its pipeline of mitochondrial targeted candidates for neurodegenerative disorders and renal diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $500.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 17, 2021